Furthermore, we observed increased expression of liver genes linked to stimulation of fatty acid oxidation such as Carnitine palmitoyl transferase 1 (Cpt1) together with down-regulated gene expression of Fatty acid synthase (Fasn) commonly up-regulated in NAFLD [40], indicating protective effects of empagliflozin in the liver. The gene discussed is CPT1A; the disease is metabolic dysfunction-associated steatotic liver disease.